Poly Medicure released its Investor Presentation for March 2026, detailing robust operational scale, highlighted by 1.8 Billion+ devices manufactured annually and presence in 125+ countries. Key focuses include technological advancement across high-growth areas like Cardiology and Orthopaedics, substantial infrastructure investments, and strategic synergy realization from recent acquisitions like Plan Health, PendraCare, and Citieffe. Financial results for 9M FY26 show consolidated revenue growth of 9.1% to ₹1340.7 Cr.
Company Scale and Operational Footprint
Poly Medicure continues to demonstrate significant scale as a unique medical devices platform. The company boasts an employee base of 3600+, holds over 390+ patents, and operates 15 manufacturing plants across 5 countries. A major operational metric is the 1.8 Billion+ devices manufacturing capacity per year. Notably, the company remains the Largest Exporter of consumable medical devices for 10 consecutive years.
The operational flywheel is powered by integrated capabilities including In-House Product R&D (390+ patents, 100+ R&D professionals in India and Europe), sophisticated Tooling, Automation, and rapid prototyping, and a strong quality framework supported by 140+ Quality & Regulatory professionals.
Moving Up the Technology Curve
The company is strategically moving towards higher technological complexity areas:
- Infusion Therapy (1997): Achieved global leadership, currently the 3rd largest IV cannula manufacturer globally.
- Renal Care (2018): The first Indian company to indigenously manufacture dialysis products.
- Critical Care (2019): Focused on ICU, neonatology, and oncology products.
- Cardiology (2024): Launched DES in India and acquired Pendracare.
- Orthopaedics (2025): Acquisition of Citieffe to build a comprehensive portfolio.
Value Driving Strategic Acquisitions
The presentation detailed the contributions and ongoing integration of strategic acquisitions:
- Plan Health (Italy): Founded in 1995, its CY24 Revenue was €8.2Mn (69% YoY growth), with post-acquisition CAGR growth of 20% annually.
- PendraCare (Netherlands): Founded in 2011, it is a specialist in the cardiology catheter business, reporting CY24 Revenue of EUR 9.9 million.
- Citieffe (Italy): Founded in 1962, it focuses on trauma solutions, reporting CY24 Revenue of €17.3Mn (15% YoY growth) and EBITDA of €3.1Mn.
Key Strategic Updates (Infrastructure & Portfolio)
Significant near-term developments are underway:
- Infrastructure: The 2nd plant at Haridwar is commercially operational. The Palwal plant will complete by end of FY27, increasing capacity for Blood Bags (50%). A Gamma sterilization facility is operational as one of the first captive facilities in India.
- Portfolio Expansion: Plans include launching IVL and DEB in Cardio soon, launching 5-6 new Critical Care products in FY27, and launching a neonatal range in Pediatrics/Neonatology in FY27.
- R&D: Over 100+ professionals across India, Italy, and Netherlands are managing a pipeline of 100+ products expected for launch over the next 3-4 years.
Financial Performance Summary (9M FY26 vs 9M FY25)
The financial data shows healthy growth across key metrics on a consolidated basis:
- Revenue from Operations: Grew by 9.1% to ₹1340.7 Cr (vs ₹1229.0 Cr).
- Gross Profit %: Improved by 192 Bps to 68.8%.
- Operating EBITDA: Increased by 2.7% to ₹345.3 Cr.
- PAT: Increased by 3.6% to ₹255.7 Cr.
Consolidated Sales Mix Analysis
Domestic sales saw accelerated growth at 17.6%, contributing 32% of total revenue in 9M FY26, up from 29% in 9M FY25. Infusion Therapy remains the largest segment at 60% of the revenue mix.
Growth Strategy Focus
The company is pursuing a dual strategy:
- Domestic Strategy: Focus on Import Substitution (replicating success across Renal, Cardiology, Critical Care), expanding clinical engagement (4,000+ Clinical Engagements), and launching 25-30 new products per year.
- International Strategy (US/Europe): Leveraging direct presence (Citieffe) and distributors (Polymed, PendraCare) to expand market share and regulatory approvals across all entities.
Source: BSE
